Newly Established Specialty Pharmaceuticals Company Equity Stake For Sale in Dublin, Ireland

- Our psoriasis cream will be the lead product, entering GMP production this year. It targets the 125 million people globally living with psoriasis, initially sold direct-to-consumer and through pharmacies in Ireland and the GCC, as a botanical alternative to expensive biologics.
- Our eczema relief cream, anti-ageing cream, and pigmentation cream follow 2 years later, expanding the dermatology range into the EU pharmacy and premium skincare channels.
- We have an oral antiviral therapeutic in pre-clinical development, targeting Herpes simplex and dengue fever. Its end users are patients and hospitals, with a prescription-based distribution model entering pharmacies and hospital formularies next year.
- We also have an oncology research division, developing botanical-derived compounds for cancer treatment. It is not patient-facing in the initial round period, its near-term "customers" are research institutions and pharma co-development partners, generating licensing and collaboration revenue after 2 years. - Proprietary botanical platform, formulation knowledge and extraction processes for azadirachtin, nimbin, gedunin, and nimbolide across three therapeutic applications.
- Trade secrets, internal R&D methodology, compound modification protocols, and formulation specifications not yet filed as patents.
- Patent pipeline, composition-of-matter patents on novel botanical molecule derivatives, planned for filing within 18 months of production launch across all three verticals.
- Brand assets and brand names.
- Scientific know-how, curated library of 3,400+ peer-reviewed studies underpinning the platform, with internal synthesis and application mapping.
- Regulatory roadmap, EMA-aligned clinical development plans, and early IND pathway documentation.
- Management and advisory network, relationships with CROs, EMA advisors, NIH reviewers, and GCC regulatory consultants.
- Ireland KDB entitlement, structural tax advantage on future qualifying patent income at 6.25% effective rate. Not applicable since the company was working with R&D development.
We are headquartered in Dublin. Shareholders / owners funded the business since year 0.